HC Wainwright Has Pessimistic Outlook of DYN FY2024 Earnings

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Stock analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Dyne Therapeutics in a report issued on Wednesday, November 13th. HC Wainwright analyst A. Fein now expects that the company will earn ($3.55) per share for the year, down from their previous estimate of ($3.06). HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.39) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q4 2024 earnings at ($1.04) EPS, FY2025 earnings at ($3.35) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($1.82) EPS and FY2028 earnings at $0.19 EPS.

DYN has been the topic of several other research reports. Chardan Capital reissued a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $43.00 to $35.00 in a report on Thursday, October 24th. Morgan Stanley raised their price target on Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. StockNews.com cut Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Finally, Stifel Nicolaus increased their price objective on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $51.40.

Dyne Therapeutics Stock Up 1.2 %

NASDAQ DYN opened at $29.68 on Monday. The company has a market cap of $3.02 billion, a PE ratio of -8.34 and a beta of 1.10. Dyne Therapeutics has a 52 week low of $10.03 and a 52 week high of $47.45. The firm’s 50-day simple moving average is $32.36 and its two-hundred day simple moving average is $35.29.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25).

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds have recently modified their holdings of the company. AQR Capital Management LLC grew its position in shares of Dyne Therapeutics by 4.3% in the 2nd quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock worth $300,000 after buying an additional 352 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after acquiring an additional 669 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Dyne Therapeutics by 24.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock valued at $123,000 after purchasing an additional 709 shares during the period. KBC Group NV raised its holdings in Dyne Therapeutics by 53.4% in the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after purchasing an additional 751 shares in the last quarter. Finally, Amalgamated Bank lifted its position in shares of Dyne Therapeutics by 39.9% in the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after purchasing an additional 796 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Insiders Place Their Bets

In other news, Director Carlo Incerti sold 16,500 shares of the firm’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $28.73, for a total transaction of $474,045.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO John Cox bought 32,000 shares of the stock in a transaction dated Wednesday, September 4th. The stock was bought at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the purchase, the chief executive officer now owns 8,000 shares in the company, valued at $264,320. The trade was a -133.33 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 176,257 shares of company stock valued at $6,193,718. 20.77% of the stock is currently owned by corporate insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.